Xeris: patent to provide IP protection for Keveyis through 2039

Xeris Pharmaceuticals has announced that its product Keveyis, approved for the treatment of primary hyperoxaluria type 2, is now protected by a patent that extends intellectual property (IP) coverage through 2039 [引用越界:1]. This extended protection is expected to provide the company with a longer period of market exclusivity, potentially supporting continued revenue generation from the drug. The patent extension reflects the company’s ongoing efforts to strengthen its IP portfolio and maintain a competitive position in its therapeutic area. Investors may view this development as a factor that could influence long-term strategic planning and financial performance. The announcement does not include projections or forecasts regarding sales or market share. The company has not disclosed additional details about the patent or its potential impact on future product development.